- Home
- AARD vs ESSA Comparison
AARD vs ESSA Comparison
Compare AARD & ESSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- ESSA
- Stock Information
- Founded
- AARD 2017
- ESSA 1916
- Country
- AARD United States
- ESSA United States
- Employees
- AARD N/A
- ESSA N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- ESSA Banks
- Sector
- AARD Health Care
- ESSA Finance
- Exchange
- AARD Nasdaq
- ESSA Nasdaq
- Market Cap
- AARD 216.6M
- ESSA 219.2M
- IPO Year
- AARD 2025
- ESSA N/A
- Fundamental
- Price
- AARD $7.74
- ESSA $18.93
- Analyst Decision
- AARD Strong Buy
- ESSA
- Analyst Count
- AARD 4
- ESSA 0
- Target Price
- AARD $31.50
- ESSA N/A
- AVG Volume (30 Days)
- AARD 113.5K
- ESSA 18.5K
- Earning Date
- AARD 01-01-0001
- ESSA 04-23-2025
- Dividend Yield
- AARD N/A
- ESSA 3.19%
- EPS Growth
- AARD N/A
- ESSA N/A
- EPS
- AARD N/A
- ESSA 1.74
- Revenue
- AARD N/A
- ESSA $67,430,000.00
- Revenue This Year
- AARD N/A
- ESSA $9.38
- Revenue Next Year
- AARD N/A
- ESSA N/A
- P/E Ratio
- AARD N/A
- ESSA $11.10
- Revenue Growth
- AARD N/A
- ESSA N/A
- 52 Week Low
- AARD $7.74
- ESSA $15.29
- 52 Week High
- AARD $19.58
- ESSA $22.22
- Technical
- Relative Strength Index (RSI)
- AARD N/A
- ESSA 40.06
- Support Level
- AARD N/A
- ESSA $18.93
- Resistance Level
- AARD N/A
- ESSA $19.38
- Average True Range (ATR)
- AARD 0.00
- ESSA 0.29
- MACD
- AARD 0.00
- ESSA 0.02
- Stochastic Oscillator
- AARD 0.00
- ESSA 22.78
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About ESSA ESSA Bancorp Inc.
ESSA Bancorp Inc is a holding company, engaged in accepting deposits from the general public and investing those deposits, together with funds generated from operations and borrowings, in residential first mortgage loans (including construction mortgage loans), commercial real estate loans, home equity loans and lines of credit and commercial and industrial loans. The company offers a variety of deposit accounts, including checking, savings and certificates of deposit. The company also offers asset management and trust services and investment services. The company also offers insurance benefit consulting services through its wholly-owned subsidiary, ESSA Advisory Services, LLC.